Unborn children missing from the world today due to biological causes.
Beyond Biological Limits
e184 is a biotechnology and neurotechnology company working to overcome the limits of human biology.
Reproduction
Reproduction has not changed in four million years. Age, anatomy, and sex still determine who can become a parent. Medicine has extended the window incrementally. Technology has barely reached it.
The global fertility rate has halved in seventy years, from 4.84 to 2.23. Today, 71% of the global population already lives in countries below replacement fertility, and 198 of 204 countries are projected to fall below replacement by 2100.
Global discussion of this decline focuses almost entirely on social and economic causes. What receives almost no attention is the parallel collapse on the biological side, where the numbers are equally staggering. Against this trajectory, biology becomes the one driver of fertility that technology can unlock.
300M+
15M+
Children never born each year, 34 every minute.
1 : 10
One unborn child for every 10 alive.
In vitro gametogenesis
~1B
Women past menopause unable to conceive.
~500M
LGBTQ+ adults unable to have children genetically related to both partners.
~110M
Women of reproductive age diagnosed as infertile.
e184 develops in vitro gametogenesis to generate functional gametes from somatic cells, restoring biological parenthood across age, sex, and anatomy.
Ectogenesis
~80M
Women of reproductive age affected by tubal disease, uterine factors, or recurrent pregnancy loss.
13.4M
Babies born preterm each year, the leading cause of death in children under five.
0%
Survival below 21 weeks. More than half of survivors at 23 weeks face lifelong disabilities.
e184 develops ectogenesis to sustain gestation outside the human body, eliminating prematurity as a cause of death, and enabling biological parenthood independent of the ability to carry a pregnancy.
Genome
The human genome carries nearly four billion years of evolution, traced back to the first ancestral cell from which all life on Earth descends. Every ancestor since has added to it: the mutations that cause disease, the variants that contribute to aging, the viral remnants and broken genes of every species and generation that came before. It is biology’s longest record of error, and modern medicine only treats its consequences. The code itself has remained untouched.
For the first time, we are no longer bound by this inheritance. The genetic code is becoming something we read, edit, and ultimately rewrite, refactoring accumulated error into a genome shaped by design rather than evolution.
- Almost every person carries genetic risk for disease. Hundreds of millions of people are affected by inherited disorders, while billions more live with polygenic diseases. The same code that drives disease also sets the pace of aging. Genome editing removes pathogenic mutations and lowers inherited risk at its source.
- A few people are born with rare protective variants: resistance to disease and genetic signatures associated with longer, healthier lifespans. Synthetic genomics makes it possible to install these deliberately, rather than leaving them to evolutionary chance.
- The long-term objective is to refactor the genome itself, removing the deadweight of evolution and rewriting the code against the failure modes of aging. Not treating the consequences of inherited biology, but redesigning the source.
e184 works across the full spectrum of genome engineering in adults — editing pathogenic mutations, installing protective variants, and ultimately refactoring the code itself — to redesign the biological foundations of human longevity.
Cognition
For most of human history, intelligence developed within the fixed biological limits of the brain. Artificial intelligence changes this for the first time. A brain–computer interface turns AI from an external tool into an integral part of the mind, allowing it to evolve beyond its biological constraints.
Direct brain–AI connection today means surgery. Invasive interfaces reach only a handful of patients, and an implant will never scale to billions. The bottleneck is the hardware. Reaching everyone requires an interface with no implants or surgery.
- Genetic potential for human intelligence has barely changed over the last several thousand years. Yet measured cognitive performance has risen dramatically within a single century, global IQ scores increased by roughly 30 points, driven by literacy, education, and technology. Human cognition responds to technological environments. The brain is not fixed.
- Learning a new technology physically rewires the brain due to its plasticity. Reading creates new links between visual and language systems. Abacus-trained children internalize calculation into visuospatial working memory and perform arithmetic without the physical device. The brain does not simply use a new technology, it develops around it.
- A brain–computer interface works the same way, but at a larger scale. Continuous interaction with a system that expands in capability allows the brain to develop around the interface, building new pathways and forms of cognition that did not previously exist. As AI continues to advance, the mind grows with it, no longer bound by the biological substrate it emerged from. The expansion of human cognition becomes open-ended.
e184 develops a non-invasive brain–computer interface based on next-generation solid-state magnetometers, high-bandwidth sensors that detect neural activity without implants. A path to native fusion of human cognition with intelligent systems, enabling brain–AI symbiosis at population scale.
Mission
Evolution has always decided how we reproduce, how our genome is written, and how we think. e184 is building the technologies required to take control of evolution and overcome the limits of human biology.
e184 is built around three programs. In vitro gametogenesis and ectogenesis support the full reproductive cycle from cell to birth outside the human body. Genome engineering prevents inherited disease, extends healthy lifespan, and ultimately refactors the genetic code. A non-invasive brain–computer interface enables direct brain–AI interaction and augments human cognition without surgery. Together, they span the full arc of human biology, from reproduction to the genome to cognition.
Where current medicine ends — women who cannot conceive or carry, babies born too early to survive, couples for whom biological parenthood is impossible — is where e184 begins. Reproduction should not be constrained by age, sex, anatomy, or the ability or willingness to carry a pregnancy.
Most causes of disease and aging are written into the genome, yet medicine still treats their downstream consequences. e184 develops genome engineering to edit pathogenic mutations, install protective variants, and rewrite the code itself. Genetic disease need not be inevitable. Aging need not be a fixed outcome.
Invasive brain–computer interfaces enable direct brain–AI integration, but surgery confines the technology to a tiny fraction of humanity. To reshape how humans interact with AI, brain–computer interfaces must be non-implantable and scale to billions.
We believe these technologies should be universally accessible. Medical necessity is the starting point.Biological freedom is the destination.
Principles
Hyperfocus
Reproduction. Genome. Cognition.
The three biological foundations of being human.
Full stack
Multiple scientific disciplines.
A single in-house research operation across biology, genomics, physics, bioinformatics, materials science, and engineering.
Long horizon
The work follows scientific timelines, not market urgency.
The science sets the pace.
Standards
Technologies affecting reproduction, the genome, and cognition carry profound and lasting consequences. Their development requires staged validation, long-term safety evaluation, and clinical oversight before broad human use. e184 develops these systems under rigorous scientific standards and clinical supervision.
Team
Kirill Eves
Founder
Marianna Krell
Chief Operating Officer
Peter Zhegin
Program Director
Aleksei Mikhalchenko
Co-Founder & Chief Science Officer, IVG
Anishur Rahman
Co-Founder & Chief Science Officer, BCI
Joseph Owen
Program Director, Ectogenesis
Pablo Hurtado Gonzalez
Chief Operating Officer, IVG
Chao-Shun Yang
Team Lead
Nuria Marti Gutierrez
Lead Embryologist
Scott Barish
Scientist
Minoo Karimi
Scientist
Dongkyeong Kim
Scientist
Yingzhen Pei
Scientist
Sushma Ram
Research Associate
Tassilo Neubauer
Bioinformatics Engineer
Sarah Bolton
Lab Operations Manager
Matthew Von Hippel
Science Communications Lead
Careers
We are hiring biologists, geneticists, physicists, bioinformaticians, materials scientists, and engineers who want to work on the questions that will define the next chapter in human biology.
If you spent your career being told that your most ambitious idea is interesting but unfundable, talk to us. That idea is probably the reason we exist.
